Last $3.20 USD
Change Today +0.12 / 3.90%
Volume 2.2M
VVUS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:00 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

vivus inc (VVUS) Snapshot

Open
$3.07
Previous Close
$3.08
Day High
$3.20
Day Low
$3.05
52 Week High
01/14/14 - $9.80
52 Week Low
12/12/14 - $2.92
Market Cap
331.8M
Average Volume 10 Days
1.9M
EPS TTM
$-0.44
Shares Outstanding
103.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VIVUS INC (VVUS)

vivus inc (VVUS) Related Businessweek News

View More BusinessWeek News

vivus inc (VVUS) Details

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II clinical studies for the treatment of obstructive sleep apnea and diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

98 Employees
Last Reported Date: 02/28/14
Founded in 1991

vivus inc (VVUS) Top Compensated Officers

Chief Executive Officer, Chief Commercial Off...
Total Annual Compensation: $212.1K
Interim Chief Financial Officer and Principal...
Total Annual Compensation: $274.8K
Senior Vice President of Business Development...
Total Annual Compensation: $398.8K
Vice President of Clinical Development
Total Annual Compensation: $419.7K
Vice President of U S Operations and General ...
Total Annual Compensation: $369.9K
Compensation as of Fiscal Year 2013.

vivus inc (VVUS) Key Developments

VIVUS Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

VIVUS Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $33.877 million compared to $27.379 million a year ago. Net loss was $15.825 million, or $0.15 per basic and diluted share compared to $48.204 million or $0.48 per basic and diluted share a year ago. Loss from operations was $7.912 million against $40.677 million a year ago. Loss from continuing operations before income taxes was $16.047 million against $48.346 million a year ago. Loss from continuing operations was $15.825 million or $0.15 per basic and diluted share against $48.379 million or $0.48 per basic and diluted share a year ago. For the nine months, the company reported total revenue of $92.449 million compared to $37.025 million a year ago. Net loss was $57.200 million, or $0.55 per basic and diluted share compared to $157.292 million or $1.56 per basic and diluted share a year ago. Loss from operations was $33.326 million against $145.919 million a year ago. Loss from continuing operations before income taxes was $57.860 million against $157.736 million a year ago. Loss from continuing operations was $57.200 million or $0.55 per basic and diluted share against $157.782 million or $1.56 per basic and diluted share a year ago.

VIVUS Inc. to Report Q3, 2014 Results on Nov 05, 2014

VIVUS Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 05, 2014

VIVUS Inc., Q3 2014 Earnings Call, Nov 05, 2014

VIVUS Inc., Q3 2014 Earnings Call, Nov 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $3.20 USD +0.12

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $3.90 USD +0.12
GlaxoSmithKline Consumer Healthcare Ltd 5,581 INR -39.00
GlaxoSmithKline PLC 1,347 GBp -1.00
Roche Holding AG SFr.279.00 CHF -2.30
View Industry Companies
 

Industry Analysis

VVUS

Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit www.vivus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.